Activated protein C-protein C inhibitor complex: A new biological marker for aortic aneurysms  by Kölbel, Tilo et al.
Activated protein C-protein C inhibitor complex:
A new biological marker for aortic aneurysms
Tilo Kölbel, MD,a Karin Strandberg, MD, PhD,b Ingrid Mattiasson, MD, PhD,a Johan Stenflo, MD,
PhD,b and Bengt Lindblad, MD, PhD,a Malmö, Sweden
Objective: The concentration of the complex between activated protein C (APC) and protein C inhibitor (PCI) is a
measure of thrombin generation. We studied whether it can provide information useful for the diagnosis and treatment
of arterial vascular disease.
Methods: Blood was obtained from 429 vascular patients admitted consecutively during September 2004 to March 2005.
The APC-PCI complex was measured by using a sandwich immunofluorometric method. The patients were divided into
cohorts according to the planned treatment and compared with a control group of healthy individuals.
Results: The APC-PCI complex concentration varied from 0.08 to 2.50 g/L. In the cohort of patients with aortic
aneurysms (n  78), the median APC-PCI value was 0.45 (10th to 90th percentile, 0.24-1.47), and values were clearly
increased compared with all other cohorts (P < .0001). Patients with carotid disease (n  73) yielded a median of 0.22
(10th to 90th percentile, 0.15-0.48). The median for claudicants (n  74) was 0.26 g/L (10th to 90th percentile,
0.15-0.75), which was higher than in those (n 97) with critical ischemia (0.20; 10th to 90th percentile, 0.13-0.36; P<
.0023). The cohort with other forms of atherosclerotic disease (n  40) had a median of 0.23 (10th to 90th percentile,
0.14-0.42), whereas the value for a cohort of 21 patients with venous disease was 0.19 (10th to 90th percentile,
0.10-0.34). The median was 0.15 (10th to 90th percentile, 0.10-0.23) for the control group (n  121).
Conclusions: Patients with atherosclerosis had an increased APC-PCI concentration that corresponded to increased
generation of thrombin. Patients with aortic aneurysm had a threefold higher median concentration than the control
group. We suggest that this remarkable increase is caused by the local activation of coagulation, and we surmise that
APC-PCI measurements can be used as a screening tool to identify patients with aortic aneurysms. (J Vasc Surg 2006;
43:935-9.)Atherosclerotic disease and the subsequent develop-
ment of arterial superimposed thrombosis may lead to
life-threatening clinical manifestations, such as myocardial
infarction, stroke, and lower limb ischemia.1-6 It is sup-
posed that these frequent thrombosis-related complica-
tions result from a prethrombotic state in which a partially
activated coagulation system produces increased levels of
thrombin.7-10 Molecular markers for increased thrombin
generation that can detect a prethrombotic state include a
prothrombin activation fragment, fragment 1 2, and the
complex formed between thrombin and its cognate serpin
inhibitor, antithrombin.11 However, these methods are not
used much in clinical practice. More recently, the complex
formed between activated protein C (APC) and the serpin
protein C inhibitor (PCI) has been shown to be a sensitive
indicator of thrombin formation and, thus, of the activation
of blood coagulation.12 An increased concentration of the
APC-PCI complex has been observed in patients with deep
vein thrombosis, pulmonary embolism, disseminated intra-
vascular coagulation, sepsis, and myocardial infarction and
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Thrombin is amultifaceted coagulation enzyme that, in
addition to its procoagulant activity, binds to the endothe-
lial cell cofactor, thrombomodulin, and activates anticoag-
ulant protein C.19 APC cleaves the membrane-bound co-
factors, factors Va and VIIIa, thus inhibiting coagulation
and limiting thrombus formation to the site of injury.20,21
APC is slowly inactivated in plasma (its half-life is approxi-
mately 20 minutes) by binding to PCI to form a 1:1
complex. The complex also has a half-life of approximately
20 minutes.
A new and sensitive sandwich immunofluorometric
assay for quantitating the APC-PCI concentration has been
devised.12 It uses a monoclonal antibody specific for the
loop-inserted form of PCI that is induced upon binding to
APC. The monoclonal antibody has no affinity for uncom-
plexed, native PCI, even though the native form has a
molar concentration approximately 104-fold higher than
that of the complex.12,22 The aim of this study was to
establish whether measurements of the concentration of
the APC-PCI complex provide information useful for the
diagnosis and treatment of patients with arterial vascular
disease. The results indicate that the method may be suit-
able for screening patients for abdominal aortic aneurysms.
METHODS
Patients. From September 2004 to March 2005, 429
patients admitted consecutively as inpatients to the Depart-
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Sweden, were enrolled in this observational study. Twelve
patients refused to take part in the study. Patients who had
been administered warfarin within 1 month of blood sam-
pling (n  46) were excluded from the study. Depending
on their planned treatment, the remaining 383 patients
were divided into 6 cohorts of patients with aortic aneu-
rysm (n 78), carotid artery disease (n 73), claudication
(n 74), critical limb ischemia (n 97), venous disease (n
 21), and other atherosclerotic disease (n  40). The
cohort with other atherosclerotic disease consisted of pa-
tients with renovascular disease, mesenteric ischemia, upper
extremity arterial disease, popliteal and femoral artery an-
eurysm, and pseudoaneurysms. The cohorts were com-
pared with a healthy control group (n  121), which
consisted of patients without medication and without clin-
ical symptoms for peripheral atherosclerotic disease, coro-
nary artery disease, and other manifestations of atheroscle-
rosis (Table I). They were recruited from the Malmö
Prevention Project, a health screening program, but were
not examined by ultrasonography or physical examination
for aortic aneurysm or asymptomatic atherosclerotic dis-
ease.23 All patients gave written informed consent to par-
ticipate in the study, which was approved by the ethics
committee of Lund University.
APC-PCI measurements. Venous blood was drawn
for measurements of the APC-PCI concentration on the
day of admission for elective procedures between 8:00 and
12:00 AM before any operation or invasive procedure was
undertaken. It was collected in 5-mL vacuum tubes (Stabi-
lyte; Biopool, Umeå, Sweden) containing citrate with a low
Table I. Basic demographics of the cohorts
Cohort (r
Aortic aneurysms (n  78)
Carotid disease (n  73)
Claudication (n  74)
Critical limb ischemia (n  97)
Venous disease (n  21)
Others (n  40)
Controls (n  121)
Table II. Concentration of the APC-PCI complex in the
Cohort
APC-P
(range; 1
Aortic aneurysms (n  78) 0.4
Carotid disease (n  73) 0.2
Claudication (n  74) 0.2
Critical limb ischemia (n  97) 0.2
Venous disease (n  21) 0.1
Others (n  40) 0.2
Controls (n  121) 0.1
APC-PCI, Activated protein C-protein C inhibitor; NS, not significant.pH, which precludes in vitro formation of the APC-PCIcomplex, and centrifuged at 3600g for 10 minutes at 4°C,
within 30 minutes of collection of the blood. The plasma
was frozen in aliquots at 70°C for later analysis.22 APC-
PCI was measured by using a previously described dissoci-
ated enhanced lanthanide fluoroimmunoassay, which has a
functional sensitivity in stabilyte-plasma of 0.032 g/L.
The reference interval in healthy control individuals was
0.10 to 0.23g/L, with amedian of 0.15g/L (n 121).
The within-run coefficient of variation was 4.8% at 0.15
g/L and 3.2% at 0.40 g/L.22 The between-run coeffi-
cient of variation was 7.1% at 0.15 g/L and 5.8% at 0.41
g/L (n  38).
Statistical analysis. Data on APC-PCI complex con-
centrations in the cohorts were considered to be nonpara-
metrically distributed and were expressed as median and
range (10th to 90th percentiles). For intercohort compar-
ison of the APC-PCI complex concentration, the Mann-
Whitney U test was used, and P  .05 was considered
significant. The independent significance of APC-PCI
complex concentrations in the cohorts was assessed by a
multiple logistic regression analysis after adjustment for age
and sex. Analyses were performed by a biostatistician on
SPSS software for Windows, version 12.0 (SPSS Inc, Chi-
cago, Ill).
RESULTS
The APC-PCI concentration varied between 0.08 and
2.50 g/L in the population of patients with vascular
disease, with a median of 0.26 g/L (10th to 90th percen-
tile, 0.15-0.71 g/L). Table II shows the APC-PCI con-
centration in the patient cohorts compared with the control
Median age, y
; 10th-90th percentile) Sex (M/F)
73 (61-82) 74/4
68 (58-78) 46/27
70 (58-80) 50/24
77 (62-88) 50/47
52 (33-72) 8/13
64 (36-79) 19/21
52 (30-75) 48/73
rts
g/L, median
0th percentile)
P value
(compared with controls)
24-1.47) .0001
15-0.48) .0035
15-0.75) .0001
13-0.36) .0295
10-0.34) NS
14-0.42) .0065
10-0.23) —angecoho
CI, 
0th-9
5 (0.
2 (0.
6 (0.
0 (0.
9 (0.
3 (0.
5 (0.group. All cohorts except that with venous disease had
JOURNAL OF VASCULAR SURGERY
Volume 43, Number 5 Kölbel et al 937significantly higher APC-PCI levels than the control group.
It is interesting to note that claudicants had significantly
higher APC-PCI levels than did patients with critical isch-
emia (P  .0023). In contrast, there was no difference in
APC-PCI levels between patients with symptomatic and
asymptomatic carotid disease (n 47 [0.22 g/L; 10th to
90th percentile, 0.16-0.48 g/L] and n 26 [0.24 g/L;
10th to 90th percentile, 0.15-0.38 g/L], respectively).
Logistic regression analysis regarding age and sex as con-
founders for APC-PCI levels showed that sex was not a
confounding factor; however, age was (P  .001).
The highest APC-PCI levels were found in the aortic
aneurysm cohort, which had a median value of 0.45 g/L
(10th to 90th percentile, 0.24-1.47 g/L)—fully threefold
higher than the control group—and these levels were sig-
nificantly higher compared not only with those of the
control group but also of all other cohorts of patients with
vascular disease (Fig). Additionally, of the 32 patients in the
aortic aneurysm cohort with APC-PCI levels less than 0.40
g/L, 7 had aneurysms without thrombus lining, 5 had
minimal amounts of thrombus lining, and 20 had ordinary
thrombus-lined aneurysms. Furthermore, of the 40 pa-
tients who were not included in the aortic aneurysm treat-
ment cohort but had APC-PCI levels greater than 0.40
g/L, 30 had been evaluated with regard to aortic pathol-
ogy: 12 had normal aortic anatomy, 7 had aortic aneu-
rysms, 2 had pseudoaneurysms, 7 had aortic thrombus
formation, and 2 had severe aortic arteriosclerosis.
DISCUSSION
Activation of the protein C anticoagulant system is a
sensitive marker of thrombin generation and, hence, of the
activation of blood coagulation.12,19 APC is slowly inhib-
ited in plasma by its cognate inhibitor, the serpin PCI.
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Fig. Box plots showing the concentration of the activated protein
C-protein C inhibitor (APC-PCI) complex in the cohorts and the
control group (bars indicate median; box, 25th-75th percentiles;
whiskers, range; circles, individual values out of the range; AA,
aortic aneurysm; CLI, critical limb ischemia).Because the PCI concentration is stable and approximately104-fold higher than the concentration of the APC-PCI
complex, the APC-PCI level accurately reflects the concen-
tration of APC. In this study, we showed that the concen-
tration of the APC-PCI complex was significantly increased
in patients with atherosclerotic disease. This was particu-
larly obvious in patients with an aortic aneurysm.
The dilated segments of aortic aneurysms are usually
filled with laminated granular thrombi, which reduce the
pathologically increased vascular diameter and normalize
the blood flow. The amount and distribution of the intralu-
minal thrombus are associated with the rate of aneurysm
growth and may also be associated with a risk for rupture of
the aneurysm.24-26 Activation of coagulation has been
shown to be present in patients with aortic abdominal
aneurysms.27,28 The increased activation of coagulation in
patients with atherosclerosis or an aortic aneurysm is pre-
sumably caused by blood passing the highly thrombogenic
surface of an ulcerated plaque or the intraluminal throm-
bus. The degree of activation may vary, depending on the
size of the thrombogenic surface, the extent to which the
blood enters into the thrombus, and the local blood pres-
sure and flow characteristics. The activation of coagulation
is reflected by the APC-PCI concentration and related to
the amount of thrombus.19 Because activation of protein C
requires healthy endothelium that expresses normal
amounts of thrombomodulin, it takes place on the surface
of intact endothelium, thus protecting these areas from the
harms of coagulation activation, such as arterial thrombo-
sis. The half-life of APC in plasma is approximately 20
minutes; this ensures that APC is also a circulating antico-
agulant, whereas thrombin itself does not pass the capillary
bed. Our results indicate that APC-PCI measurements may
provide a useful tool for follow-up and for screening indi-
viduals for aortic aneurysms, because other markers have so
far failed in screening for this disorder in clinical studies.29
Patients with atherosclerotic disease other than aortic
aneurysms also had significantly increased APC-PCI levels.
The focal rupture, ulceration, and erosion of the luminal
surface of atheromatous plaques result in exposure of
highly thrombogenic substances that activate coagulation
and generation of thrombin and also activate the protein C
anticoagulant system.4,7,10 Other coagulation markers are
increased in atherosclerotic diseases, but, to date, none has
been introduced into clinical practice.7,30,31 APC-PCI lev-
els may have implications for individualizing prereconstruc-
tive, perireconstructive, and postreconstructive anticoagu-
lative treatment. The activation of coagulation, as revealed
by the APC-PCI concentration, may be associated with a
risk for superimposed thrombosis in atherosclerotic pa-
tients in general and for thrombosis in the early postrecon-
structive period.
Claudicants had significantly higher APC-PCI levels
than did patients with critical limb ischemia, thus indicating
that thrombin generation and coagulation activation might
be higher in patients with claudication compared with
patients with critical limb ischemia. Peripheral arterial dis-
ease is known to be associated with coagulation activation,
but a correlation with the severity of the clinical symptoms
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exposure to the bloodstream may be less in patients with
critical limb ischemia because atherosclerotic areas are less
exposed as a result of more extensive occlusions and a more
pronounced reduction of the blood flow.
Recent studies on carotid plaque structure showed
morphologic differences associated with symptomatic ca-
rotid disease, thus suggesting that plaques which are encas-
ing the thrombogenic surface with fibrocalcified tissue have
a reduced probability for ipsilateral symptoms of cerebral
ischemia.32 However, we could not observe a difference in
thrombin activation between patients with asymptomatic
and symptomatic carotid disease.
In conclusion, patients with atherosclerotic disease ex-
hibit significantly increased concentrations of APC-PCI,
particularly patients with aortic aneurysms, who exhibit a
remarkable threefold increase in the level of the complex.
We did not evaluate aortic pathology in all patients in-
cluded in this observational study, because the relationship
of aortic aneurysms and high APC-PCI levels was not
previously known. Additionally, the control group in this
study was not age- and sex-matched to the study patients,
and comorbidities and medications of the study patients
were not analyzed. These are weaknesses that limit the
conclusions of this study. More research is required to
resolve this and the other important questions of clinical
significance mentioned previously. Because this was a
hypothesis-generating study on the possible value of a new
method to measure coagulation activation in arterial vascu-
lar patients, prospective studies are now planned to assess
the relationship of the APC-PCI concentration to aortic
pathology and peripheral arterial disease. Nevertheless, the
high levels of APC-PCI in aortic aneurysm patients indicate
that this test may be suitable for screening purposes.
The skillful statistical assistance of Håkan Lövkvist,
Region Skane Competence Center for Clinical Research, is
greatly acknowledged.
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